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Since the very ﬁrst description, in its homozygous variant
known as the Jervell and Lange-Nielsen syndrome (1,2), of
the congenital long QT syndrome (LQTS) (3), it had been
evident that the most critical trigger for sudden death was
represented by an abrupt activation of the sympathetic
nervous system. Indeed, the tragic deaths of those 3 little
siblings occurred while they were running, playing, or
swimming (1). The recognition of the much more common
heterozygous form, initially called Romano-Ward syndrome
before the introduction in 1975 of the acronym LQTS (4),
brought together the concept that the single most importantSee page 819trigger for lethal arrhythmias in LQTS was sympathetic
hyperactivity (4). This partial truth was the consequence of
the fact that in the pre-genetic era, most of the few diag-
noses made were in severe cases with the striking association
between collapse and physical or emotional stress and that
probably most of them were in patients who would now be
labeled LQT1. Not by chance, already in 1985, the possi-
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from the Netherlands Heart Foundation (grant NHS2010B216).unknown intracardiac abnormality that decreases electrical
stability and makes the myocardium more vulnerable to the
effect of sympathetic discharges. In this case the sympathetic
nervous system, acting mostly through the quantitatively
dominant left stellate ganglion, would merely represent the
trigger for the ventricular tachyarrhythmias that lead to the
death of patients with LQTS” (5). This hypothesis,
advanced 10 years before the identiﬁcation of the ﬁrst LQTS
genes, also strengthened the concept that therapy should
involve antiadrenergic interventions such as beta-blockers
and left cardiac sympathetic denervation, which still repre-
sent the key to proper management (6).
The identiﬁcation of KvLQT1 as the gene for LQT1 (7)
shifted the focus to a speciﬁc current, IKs, and represented
a giant leap forward in the search for underlying mecha-
nisms. IKs is activated by fast heart rates and by catechol-
amines, and it shortens ventricular repolarization, thus
providing a physiological protection against the possibility of
arrhythmias at fast rates. This may help explain why,
compared with LQT2 and LQT3 patients, LQT1 patients
are at much higher risk during exercise. Because of their
malfunctioning IKs channels, it is expected that their hearts
shorten their QT intervals during tachycardia less effectively
than the hearts of normal individuals do. Indeed, when the
triggers for lethal events where subdivided between exercise,
emotion, and rest, it turned out that 90% of LQT1 patients
had these events during exercise or emotion (8). That study
on 670 symptomatic patients of known genotype established
that sympathetic activation is the main arrhythmogenic
trigger for LQT1 patients (8).
As the genotype-phenotype correlation studies evolved, it
became evident that the site of the mutation (e.g., trans-
membrane versusC-terminal), the type ofmutation (missense
versus nonmissense), the biophysical defect (dominant-
negative versus haploinsufﬁciency), and mutation-speciﬁc
characteristics could all have important clinical impacts.
However, neither the localization of a mutation nor its
cellular electrophysiological effect is sufﬁcient to consistently
predict the impact on clinical manifestations.
The most striking example of mutation-speciﬁc behavior
is probably that of KCNQ1-A341V, a relative hotspot
mutation characterized by unusual clinical severity demon-
strated by 80% of the patients being symptomatic, with
>30% experiencing cardiac arrest or sudden death (9,10).
What is puzzling is that A341V is only a mildly dominant-
negative mutation producing a z50% loss of IKs. A further
step toward understanding the genotype-phenotype rela-
tionship came by the observation that the dominant-
negative effect of KCNQ1-A341V also manifests as
a failure to modulate IKs by beta-adrenergic signaling;
heterozygous expression of KCNQ1-A341V in cultured cells
completely disabled cyclic adenosine monophosphate
(cAMP)-dependent up-regulation of IKs (11). The quest for
molecular explanations revealed a signiﬁcant reduction of
KCNQ1 phosphorylation at S27 (11), the N-terminal site
long recognized as critical for phosphorylation (12).
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S27D (known to enhance wild-type IKs just like natural
cAMP stimulation (13) rescued the loss of up-regulation
conferred by KCNQ1-A341V through a mechanism
requiring the presence of the A-kinase anchoring protein
Yotiao (11). These data nicely illustrate the intricate regu-
lation of IKs by multiple elements of its macromolecular
channel complex. In principle, defects at any level may cause
loss-of-function, as exempliﬁed by the identiﬁcation of
a LQTS-causing mutation in Yotiao, which inhibits the
functional response of IKs to cAMP (14). Contemporary
studies of the molecular-biophysical defects underlying
LQTS thus focus on the regulatory mechanisms of ion-
channel expression and function, much beyond the charac-
terization of basal current only.
In this issue of the Journal, Wu et al. (15) describe the
pathogenic consequences of another KCNQ1 mutation,
G269S, residing in the S5 segment of the channel. The
investigators have performed a meticulous study by linking
the cellular characterization of basal and cAMP-inert
mutant IKs to a thorough QT analysis in G269S carriers
from 4 unrelated families. Most of the 11 carriers had
normal-to-borderline corrected QT intervals at rest, but
abnormal corrected QT adaptation during exercise. One
family member had died suddenly and another, a 22-year-
old woman, experienced syncope while dancing. She has
been well on beta-blockade thereafter. Various important
messages emerge from this act of modern LQT1 pheno-
typing. First, these data stress again how crucial it is to
take good notice of the patient’s symptoms and family
history, as well as to look beyond the actual QT interval in
case of suspected LQTS. A borderline-normal QT may
still be associated with a severe risk of arrhythmia, as
postulated long ago (16). Careful examination during
dynamic conditions, including exercise testing (17,18),
epinephrine challenging (19), baroreﬂex sensitivity testing
(20), or postural change (21) may be necessary to unmask
the presence and severity of QT pathology in LQTS-
mutation carriers. Second, at the cellular level, Wu et al.
(15) elegantly present yet another example of a heterozy-
gous KCNQ1 mutation with a dominant-negative impact
on cAMP-dependent up-regulation, after A341V (11) and
mutations in cytoplasmic loops S2-S3 and S4-S5 (22). It
remains to be elucidated whether reduced KCNQ1 phos-
phorylation could underlie this loss-of-function by G269S
(Is it protein kinase A-dependent? Is N-terminal S27
involved? More generally, one is curious to understand
why mutations at so many different locations of the
KCNQ1 protein (S2-S3 and S4-S5 loops, S5 segment, S6
segment) all confer defective regulation of IKs by cAMP.
Finally and intriguingly, a novel molecular aspect is
suggested by the observation of Wu et al. (15) that
G269S-mutant IKs is not rescued by the phosphomimetic
substitution S27D, unlike the ﬁndings for A341V (11).
Which post-phosphorylation defect hinders IKs enhance-
ment in this condition?Recent studies involving in silico modeling have focused on
the correlation of mutation-speciﬁc IKs-channel dysfunction
with patient phenotype in LQT1 for the prediction of
arrhythmia risk, with promising results when the pa-
tient’s corrected QT interval provided less than clear-cut
information (23). Although the study by Wu et al. (15) did
not incorporate computational modeling of repolarization
gradients and proarrhythmic instability, the experimental
addition of cAMP-dependent regulation of IKs and its
pathological loss, beyond a thorough QT analysis, improves
our possibilities to assess cardiac risk. These and other
incremental understandings of the genotype-phenotype
relations will eventually be incorporated in translational
models for personalized management of LQTS. In this
regard, improved multiscale modeling of the integrated heart
is awaited. Another key to better understand phenotypic
differences and outcome in LQT1 patients will be to examine
the genetic mutation in its genomic context, as provided by
stem-cell technology (24).
It is evident how the most recent studies are conﬁrming
the importance of neural mechanisms in the onset of stress-
induced arrhythmias, thus conﬁrming the 1985 hypothesis
(5), and progressively pointing to a more complex relation-
ship between cardiac sympathetic nerves and lethal
arrhythmias in LQTS.
The question now is whether we will ultimately be able to
develop diagnostic modalities by which we can recognize
phenotypic signatures of ion-channel mutations at the
patient level and predict clinical outcomes. In any scenario,
for LQT1, such a translational approach should encompass
the cellular investigation of cAMP regulation of IKs (i.e.,
a “molecular stress test”) besides basal current characteristics.
At the integrative level, the patient’s responsiveness to
sympathetic challenges should be examined in a safe,
controlled manner. Bringing these levels together is crucial
for a more thorough understanding of the genotype-
phenotype interaction, and the present study by the group
led by Dr. Horie represents another step forward.Acknowledgment
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